UF Team Plays Major Role in Success of Newly Approved Duchenne Muscular Dystrophy Drug

Duchenne muscular dystrophy families, advocates and health care providers celebrated a milestone in March with the U.S. Food and Drug Administration’s approval of the first nonsteroidal drug for the treatment of Duchenne.

A person wearing black tight and colorful shoes with flower on it, playing the game hopscotch outside, with their left food on the number three and their right foot up in the air.

I can’t say enough positive things about the entire team. Everyone has consistently gone out of their way to accommodate us & support us. We’ve been participating for so many years that our annual trips feel like we’re reuniting with our good friends.

Very important if we can eliminate intrusive biopsies as a necessary requirement for clinical trial evaluation. MRIs are a much preferred “gold standard”.

The study has been very exciting. Discovering new tools that can help in the development of more studies and clinical trials for Becker muscular dystrophy. I feel like people are beginning to recognize BMD now.

FOR PARTICIPANTS

Participate in a Research Study

FOR SPONSORS

Request Clinical Trial Services or Data Sharing

SIGN UP FOR INSIGHTS, NEWS, AND UPDATES

From the Leaders in Becker and Duchenne Research

"*" indicates required fields

Research Partners: